data_1m42_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1m42 _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.475 0.816 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -75.64 -179.73 5.41 Favored 'Trans proline' 0 N--CA 1.455 -0.791 0 C-N-CA 122.472 2.115 . . . . 0.0 110.279 176.239 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 18.9 mmtp 68.24 -148.06 0.13 Allowed 'General case' 0 CA--C 1.536 0.417 0 C-N-CA 124.881 1.272 . . . . 0.0 111.368 173.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -65.33 121.97 16.05 Favored 'General case' 0 CA--C 1.522 -0.117 0 CA-C-N 119.251 0.932 . . . . 0.0 110.843 -173.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 6.1 t -126.36 -47.65 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 C-N-CA 124.598 1.159 . . . . 0.0 110.088 -173.156 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 48.4 m -133.06 165.86 23.76 Favored 'General case' 0 N--CA 1.461 0.08 0 CA-C-O 121.216 0.531 . . . . 0.0 110.379 179.645 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 23.9 p -158.26 171.5 20.08 Favored 'General case' 0 N--CA 1.445 -0.709 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 69.2 m -145.72 79.37 11.24 Favored Pre-proline 0 C--N 1.328 -0.346 0 N-CA-C 104.962 -2.236 . . . . 0.0 104.962 153.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_endo -93.74 -83.07 0.0 OUTLIER 'Trans proline' 0 N--CA 1.44 -1.634 0 C-N-CA 123.755 2.97 . . . . 0.0 108.254 -176.211 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . 177.55 41.06 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 127.128 2.171 . . . . 0.0 111.141 177.273 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -51.28 94.72 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 124.47 1.108 . . . . 0.0 112.947 -174.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 57.41 33.07 65.17 Favored Glycine 0 CA--C 1.53 1.022 0 CA-C-N 115.848 -0.614 . . . . 0.0 112.319 -176.356 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 22.2 m -72.03 116.89 12.97 Favored 'General case' 0 N--CA 1.454 -0.23 0 CA-C-N 118.107 0.953 . . . . 0.0 108.45 173.598 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -116.73 111.8 20.29 Favored 'General case' 0 CA--C 1.514 -0.413 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 176.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 163.2 -55.34 0.29 Allowed Glycine 0 C--O 1.224 -0.516 0 C-N-CA 120.598 -0.81 . . . . 0.0 112.373 -175.37 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -157.17 146.75 20.43 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 117.728 0.764 . . . . 0.0 109.023 -167.05 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -47.25 133.26 9.55 Favored Pre-proline 0 CA--C 1.535 0.399 0 CA-C-O 119.083 -0.484 . . . . 0.0 111.404 168.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 83.7 Cg_endo -69.6 142.23 48.06 Favored 'Trans proline' 0 N--CA 1.45 -1.063 0 C-N-CA 121.789 1.659 . . . . 0.0 108.354 170.2 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -61.11 -42.57 98.76 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-O 121.263 0.554 . . . . 0.0 110.961 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.7 pttt -156.55 169.32 24.92 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 106.017 -1.845 . . . . 0.0 106.017 -179.388 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 1.8 mt -123.32 108.9 22.05 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.205 0 C-N-CA 124.339 1.056 . . . . 0.0 108.813 -179.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -97.75 136.83 37.54 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 124.684 1.194 . . . . 0.0 109.302 -177.089 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 53.4 mt -135.42 122.62 21.6 Favored 'General case' 0 N--CA 1.466 0.336 0 C-N-CA 124.812 1.245 . . . . 0.0 108.308 -178.639 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 29.3 m170 -123.91 112.65 17.49 Favored 'General case' 0 C--O 1.238 0.497 0 C-N-CA 123.716 0.806 . . . . 0.0 111.074 -165.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 8.3 m-85 -100.83 143.77 30.59 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 123.743 0.817 . . . . 0.0 110.688 -176.79 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 4.4 m -71.39 -43.44 66.83 Favored 'General case' 0 C--O 1.227 -0.099 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 170.55 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -78.09 134.16 37.76 Favored 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 179.248 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -78.19 70.94 4.63 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 107.055 -1.461 . . . . 0.0 107.055 162.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 3.5 pp -77.8 -170.54 1.91 Allowed 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 156.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 24.4 t 62.17 80.51 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.528 0.108 0 C-N-CA 125.327 1.451 . . . . 0.0 111.581 -168.491 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 62.8 m -75.41 -71.02 0.39 Allowed 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 160.01 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 16.7 tp60 -162.48 46.08 0.15 Allowed 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 123.133 0.573 . . . . 0.0 110.637 179.26 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 90.7 m-85 -142.6 21.72 2.0 Favored 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 123.146 0.578 . . . . 0.0 112.272 -171.31 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 43.3 t -111.4 162.8 14.68 Favored 'General case' 0 CA--C 1.529 0.163 0 C-N-CA 124.146 0.978 . . . . 0.0 109.886 -174.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -166.22 174.14 41.75 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.623 -0.991 . . . . 0.0 110.623 173.28 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -156.62 157.9 36.09 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 173.161 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 85.5 mttt -146.58 170.35 17.09 Favored 'General case' 0 N--CA 1.454 -0.228 0 C-N-CA 123.962 0.905 . . . . 0.0 108.809 171.647 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 14.7 tp -131.47 127.23 36.92 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 -175.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 5.2 m -118.37 132.77 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.34 0 C-N-CA 123.576 0.751 . . . . 0.0 110.16 -179.349 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 27.3 ttt -81.53 82.79 7.19 Favored 'General case' 0 N--CA 1.446 -0.628 0 C-N-CA 124.836 1.254 . . . . 0.0 107.69 -178.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 11.4 m -81.06 58.26 3.41 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 125.054 1.341 . . . . 0.0 108.15 175.304 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -63.35 -59.63 4.45 Favored 'General case' 0 N--CA 1.456 -0.131 0 O-C-N 121.381 -0.824 . . . . 0.0 112.901 -173.558 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 3.6 ttt -157.09 123.34 2.52 Favored Pre-proline 0 N--CA 1.453 -0.308 0 N-CA-C 107.448 -1.316 . . . . 0.0 107.448 -172.35 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -79.05 44.19 1.64 Allowed 'Trans proline' 0 CA--C 1.537 0.656 0 C-N-CA 122.448 2.099 . . . . 0.0 111.086 -176.443 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -65.25 -53.33 33.59 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 109.931 -1.268 . . . . 0.0 109.931 -176.191 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 25.5 mmt -89.99 94.36 9.77 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 167.38 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 24.2 tt0 23.35 60.39 0.04 OUTLIER 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 129.248 3.019 . . . . 0.0 113.927 169.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 21.3 t-80 56.16 42.13 28.57 Favored 'General case' 0 CA--C 1.538 0.487 0 CA-C-N 115.516 -0.765 . . . . 0.0 112.755 169.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 67.8 m -93.04 90.33 0.43 Allowed Pre-proline 0 CA--C 1.541 0.612 0 C-N-CA 124.743 1.217 . . . . 0.0 111.965 175.275 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -74.79 170.37 20.52 Favored 'Trans proline' 0 N--CA 1.458 -0.585 0 C-N-CA 122.377 2.051 . . . . 0.0 110.343 172.31 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 25.3 mtt -123.68 120.66 33.38 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 123.149 0.58 . . . . 0.0 111.501 176.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.91 128.43 35.99 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 123.288 0.635 . . . . 0.0 110.686 177.291 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -106.22 162.27 5.23 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.452 0 C-N-CA 124.281 1.032 . . . . 0.0 110.669 -177.754 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 90.8 mttt -77.51 115.53 17.35 Favored 'General case' 0 C--O 1.234 0.287 0 C-N-CA 123.71 0.804 . . . . 0.0 110.726 177.362 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -137.2 152.93 50.44 Favored 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 125.138 1.375 . . . . 0.0 108.928 171.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -109.14 138.31 45.68 Favored 'General case' 0 N--CA 1.447 -0.6 0 C-N-CA 126.086 1.754 . . . . 0.0 108.366 174.42 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -101.41 119.66 49.91 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 106.642 -1.614 . . . . 0.0 106.642 173.166 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 50.1 m -119.41 178.17 4.64 Favored 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 106.652 -1.611 . . . . 0.0 106.652 174.383 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -128.46 159.92 22.05 Favored Glycine 0 N--CA 1.449 -0.489 0 N-CA-C 108.592 -1.803 . . . . 0.0 108.592 166.681 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -73.67 -173.41 27.19 Favored Glycine 0 CA--C 1.528 0.867 0 N-CA-C 108.956 -1.657 . . . . 0.0 108.956 165.524 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -45.89 -57.09 6.3 Favored Glycine 0 CA--C 1.53 0.98 0 C-N-CA 123.406 0.527 . . . . 0.0 112.105 -178.51 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -79.95 129.95 68.54 Favored Pre-proline 0 CA--C 1.535 0.372 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.398 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -64.16 -0.76 3.02 Favored 'Trans proline' 0 CA--C 1.541 0.86 0 C-N-CA 122.975 2.45 . . . . 0.0 114.528 178.663 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 28.9 pttt -81.08 -12.43 59.29 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 124.179 0.992 . . . . 0.0 111.545 172.341 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 19.4 m -110.35 102.02 10.69 Favored 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 125.998 1.719 . . . . 0.0 107.688 -173.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -85.94 145.82 26.97 Favored 'General case' 0 CA--C 1.53 0.197 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 175.571 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 39.2 t -138.77 105.98 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.208 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 176.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 1.7 mp -92.3 125.2 44.95 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.398 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 178.774 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -110.77 118.24 48.89 Favored Pre-proline 0 N--CA 1.451 -0.421 0 C-N-CA 126.132 1.773 . . . . 0.0 108.694 177.4 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -63.51 133.64 40.85 Favored 'Trans proline' 0 N--CA 1.451 -0.983 0 N-CA-C 108.725 -1.298 . . . . 0.0 108.725 168.364 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -87.33 -37.98 16.64 Favored 'General case' 0 N--CA 1.454 -0.252 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.1 t -88.41 137.63 30.6 Favored Pre-proline 0 CA--C 1.532 0.27 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 174.198 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -63.09 123.56 12.42 Favored 'Trans proline' 0 N--CA 1.451 -1.017 0 C-N-CA 121.733 1.622 . . . . 0.0 109.707 177.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 71.5 mt -73.83 117.4 15.56 Favored 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -179.467 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -82.65 179.09 7.89 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 124.58 1.152 . . . . 0.0 110.433 174.115 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -56.53 149.09 17.96 Favored 'General case' 0 N--CA 1.45 -0.453 0 CA-C-N 114.14 -1.391 . . . . 0.0 110.046 170.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 147.61 -147.15 17.63 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 29.5 m -143.23 144.25 32.07 Favored 'General case' 0 N--CA 1.452 -0.33 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 174.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -150.96 142.14 23.18 Favored 'General case' 0 N--CA 1.447 -0.625 0 N-CA-C 108.466 -0.938 . . . . 0.0 108.466 -159.428 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 19.6 tttt -124.51 124.74 42.94 Favored 'General case' 0 N--CA 1.453 -0.3 0 C-N-CA 123.883 0.873 . . . . 0.0 108.932 173.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.3 t -82.53 128.59 38.58 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 N-CA-C 105.453 -2.054 . . . . 0.0 105.453 165.079 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 50.3 m-20 -107.89 117.95 35.47 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 105.799 -1.926 . . . . 0.0 105.799 166.493 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 43.0 p-90 -112.27 149.38 32.43 Favored 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 123.654 0.781 . . . . 0.0 109.337 179.245 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 97.9 mtt180 -137.46 83.66 2.0 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 124.407 1.083 . . . . 0.0 108.68 -172.459 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -87.11 143.82 27.14 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 122.616 0.366 . . . . 0.0 111.086 178.594 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 54.8 t -149.43 152.78 11.6 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 C-N-CA 124.629 1.172 . . . . 0.0 108.517 -174.351 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 5.5 t -103.97 176.44 5.15 Favored 'General case' 0 CA--C 1.529 0.172 0 C-N-CA 123.865 0.866 . . . . 0.0 111.669 177.471 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -58.15 -57.77 11.39 Favored 'General case' 0 CA--C 1.53 0.174 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 166.42 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -62.69 -58.39 7.64 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 124.803 1.241 . . . . 0.0 110.314 -161.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.9 t 174.54 -160.11 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 128.092 2.557 . . . . 0.0 105.228 -176.411 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 3.6 t-80 67.82 84.79 0.15 Allowed Pre-proline 0 N--CA 1.455 -0.205 0 C-N-CA 126.074 1.75 . . . . 0.0 109.899 166.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -68.23 163.54 35.81 Favored 'Trans proline' 0 N--CA 1.441 -1.566 0 N-CA-C 108.899 -1.231 . . . . 0.0 108.899 171.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -126.37 112.35 29.47 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.588 0 N-CA-C 103.251 -2.87 . . . . 0.0 103.251 150.368 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.25 148.97 29.22 Favored 'General case' 0 CA--C 1.509 -0.632 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 165.917 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -171.76 178.28 44.11 Favored Glycine 0 N--CA 1.446 -0.652 0 CA-C-N 114.098 -1.41 . . . . 0.0 111.185 -163.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -156.0 161.35 40.49 Favored 'General case' 0 N--CA 1.444 -0.756 0 C-N-CA 123.849 0.859 . . . . 0.0 111.48 -177.328 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 76.6 t -135.73 137.17 49.6 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.257 0 C-N-CA 125.999 1.72 . . . . 0.0 108.477 169.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 14.7 t -112.38 147.34 36.63 Favored 'General case' 0 N--CA 1.464 0.238 0 C-N-CA 125.17 1.388 . . . . 0.0 109.831 -179.254 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -158.34 161.03 37.58 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 123.576 0.75 . . . . 0.0 111.067 -178.128 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 27.3 mttp -123.29 141.13 52.31 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 125.263 1.425 . . . . 0.0 110.244 177.673 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 42.5 t -117.14 118.44 58.7 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 106.652 -1.611 . . . . 0.0 106.652 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 31.7 mmtt . . . . . 0 C--O 1.249 1.069 0 CA-C-O 116.567 -1.682 . . . . 0.0 109.818 170.351 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.475 0.816 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -75.64 -179.73 5.41 Favored 'Trans proline' 0 N--CA 1.455 -0.791 0 C-N-CA 122.472 2.115 . . . . 0.0 110.279 176.239 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 18.9 mmtp 68.24 -148.06 0.13 Allowed 'General case' 0 CA--C 1.536 0.417 0 C-N-CA 124.881 1.272 . . . . 0.0 111.368 173.705 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -65.33 121.97 16.05 Favored 'General case' 0 CA--C 1.522 -0.117 0 CA-C-N 119.251 0.932 . . . . 0.0 110.843 -173.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 6.1 t -126.36 -47.65 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 C-N-CA 124.598 1.159 . . . . 0.0 110.088 -173.156 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 48.4 m -133.06 165.86 23.76 Favored 'General case' 0 N--CA 1.461 0.08 0 CA-C-O 121.216 0.531 . . . . 0.0 110.379 179.645 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 23.9 p -158.26 171.5 20.08 Favored 'General case' 0 N--CA 1.445 -0.709 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 69.2 m -145.72 79.37 11.24 Favored Pre-proline 0 C--N 1.328 -0.346 0 N-CA-C 104.962 -2.236 . . . . 0.0 104.962 153.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_endo -93.74 -83.07 0.0 OUTLIER 'Trans proline' 0 N--CA 1.44 -1.634 0 C-N-CA 123.755 2.97 . . . . 0.0 108.254 -176.211 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . 177.55 41.06 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 127.128 2.171 . . . . 0.0 111.141 177.273 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -51.28 94.72 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 124.47 1.108 . . . . 0.0 112.947 -174.822 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 57.41 33.07 65.17 Favored Glycine 0 CA--C 1.53 1.022 0 CA-C-N 115.848 -0.614 . . . . 0.0 112.319 -176.356 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 22.2 m -72.03 116.89 12.97 Favored 'General case' 0 N--CA 1.454 -0.23 0 CA-C-N 118.107 0.953 . . . . 0.0 108.45 173.598 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -116.73 111.8 20.29 Favored 'General case' 0 CA--C 1.514 -0.413 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 176.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 163.2 -55.34 0.29 Allowed Glycine 0 C--O 1.224 -0.516 0 C-N-CA 120.598 -0.81 . . . . 0.0 112.373 -175.37 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -157.17 146.75 20.43 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 117.728 0.764 . . . . 0.0 109.023 -167.05 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ALA . . . . . 0.442 ' H ' HG13 ' A' ' 101' ' ' VAL . . . -47.25 133.26 9.55 Favored Pre-proline 0 CA--C 1.535 0.399 0 CA-C-O 119.083 -0.484 . . . . 0.0 111.404 168.789 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 83.7 Cg_endo -69.6 142.23 48.06 Favored 'Trans proline' 0 N--CA 1.45 -1.063 0 C-N-CA 121.789 1.659 . . . . 0.0 108.354 170.2 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -61.11 -42.57 98.76 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-O 121.263 0.554 . . . . 0.0 110.961 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.7 pttt -156.55 169.32 24.92 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 106.017 -1.845 . . . . 0.0 106.017 -179.388 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 1.8 mt -123.32 108.9 22.05 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.205 0 C-N-CA 124.339 1.056 . . . . 0.0 108.813 -179.173 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -97.75 136.83 37.54 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 124.684 1.194 . . . . 0.0 109.302 -177.089 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 53.4 mt -135.42 122.62 21.6 Favored 'General case' 0 N--CA 1.466 0.336 0 C-N-CA 124.812 1.245 . . . . 0.0 108.308 -178.639 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 29.3 m170 -123.91 112.65 17.49 Favored 'General case' 0 C--O 1.238 0.497 0 C-N-CA 123.716 0.806 . . . . 0.0 111.074 -165.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 8.3 m-85 -100.83 143.77 30.59 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 123.743 0.817 . . . . 0.0 110.688 -176.79 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 4.4 m -71.39 -43.44 66.83 Favored 'General case' 0 C--O 1.227 -0.099 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 170.55 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -78.09 134.16 37.76 Favored 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 179.248 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 58.9 t-20 -78.19 70.94 4.63 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 107.055 -1.461 . . . . 0.0 107.055 162.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.738 HD12 HG23 ' A' ' 30' ' ' VAL . 3.5 pp -77.8 -170.54 1.91 Allowed 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 156.588 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.738 HG23 HD12 ' A' ' 29' ' ' LEU . 24.4 t 62.17 80.51 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.528 0.108 0 C-N-CA 125.327 1.451 . . . . 0.0 111.581 -168.491 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 62.8 m -75.41 -71.02 0.39 Allowed 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 160.01 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 16.7 tp60 -162.48 46.08 0.15 Allowed 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 123.133 0.573 . . . . 0.0 110.637 179.26 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 90.7 m-85 -142.6 21.72 2.0 Favored 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 123.146 0.578 . . . . 0.0 112.272 -171.31 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' SER . . . . . 0.487 ' HB2' HG22 ' A' ' 30' ' ' VAL . 43.3 t -111.4 162.8 14.68 Favored 'General case' 0 CA--C 1.529 0.163 0 C-N-CA 124.146 0.978 . . . . 0.0 109.886 -174.757 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -166.22 174.14 41.75 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.623 -0.991 . . . . 0.0 110.623 173.28 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -156.62 157.9 36.09 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 173.161 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 85.5 mttt -146.58 170.35 17.09 Favored 'General case' 0 N--CA 1.454 -0.228 0 C-N-CA 123.962 0.905 . . . . 0.0 108.809 171.647 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.412 HD11 ' HB3' ' A' ' 79' ' ' TYR . 14.7 tp -131.47 127.23 36.92 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 -175.658 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 5.2 m -118.37 132.77 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.34 0 C-N-CA 123.576 0.751 . . . . 0.0 110.16 -179.349 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 27.3 ttt -81.53 82.79 7.19 Favored 'General case' 0 N--CA 1.446 -0.628 0 C-N-CA 124.836 1.254 . . . . 0.0 107.69 -178.83 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.413 ' O ' HG22 ' A' ' 41' ' ' THR . 11.4 m -81.06 58.26 3.41 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 125.054 1.341 . . . . 0.0 108.15 175.304 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -63.35 -59.63 4.45 Favored 'General case' 0 N--CA 1.456 -0.131 0 O-C-N 121.381 -0.824 . . . . 0.0 112.901 -173.558 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 3.6 ttt -157.09 123.34 2.52 Favored Pre-proline 0 N--CA 1.453 -0.308 0 N-CA-C 107.448 -1.316 . . . . 0.0 107.448 -172.35 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -79.05 44.19 1.64 Allowed 'Trans proline' 0 CA--C 1.537 0.656 0 C-N-CA 122.448 2.099 . . . . 0.0 111.086 -176.443 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -65.25 -53.33 33.59 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 109.931 -1.268 . . . . 0.0 109.931 -176.191 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 25.5 mmt -89.99 94.36 9.77 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 167.38 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 24.2 tt0 23.35 60.39 0.04 OUTLIER 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 129.248 3.019 . . . . 0.0 113.927 169.779 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 21.3 t-80 56.16 42.13 28.57 Favored 'General case' 0 CA--C 1.538 0.487 0 CA-C-N 115.516 -0.765 . . . . 0.0 112.755 169.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 67.8 m -93.04 90.33 0.43 Allowed Pre-proline 0 CA--C 1.541 0.612 0 C-N-CA 124.743 1.217 . . . . 0.0 111.965 175.275 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -74.79 170.37 20.52 Favored 'Trans proline' 0 N--CA 1.458 -0.585 0 C-N-CA 122.377 2.051 . . . . 0.0 110.343 172.31 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 25.3 mtt -123.68 120.66 33.38 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 123.149 0.58 . . . . 0.0 111.501 176.152 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.91 128.43 35.99 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 123.288 0.635 . . . . 0.0 110.686 177.291 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -106.22 162.27 5.23 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.452 0 C-N-CA 124.281 1.032 . . . . 0.0 110.669 -177.754 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 90.8 mttt -77.51 115.53 17.35 Favored 'General case' 0 C--O 1.234 0.287 0 C-N-CA 123.71 0.804 . . . . 0.0 110.726 177.362 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -137.2 152.93 50.44 Favored 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 125.138 1.375 . . . . 0.0 108.928 171.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -109.14 138.31 45.68 Favored 'General case' 0 N--CA 1.447 -0.6 0 C-N-CA 126.086 1.754 . . . . 0.0 108.366 174.42 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -101.41 119.66 49.91 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 106.642 -1.614 . . . . 0.0 106.642 173.166 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 50.1 m -119.41 178.17 4.64 Favored 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 106.652 -1.611 . . . . 0.0 106.652 174.383 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -128.46 159.92 22.05 Favored Glycine 0 N--CA 1.449 -0.489 0 N-CA-C 108.592 -1.803 . . . . 0.0 108.592 166.681 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -73.67 -173.41 27.19 Favored Glycine 0 CA--C 1.528 0.867 0 N-CA-C 108.956 -1.657 . . . . 0.0 108.956 165.524 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -45.89 -57.09 6.3 Favored Glycine 0 CA--C 1.53 0.98 0 C-N-CA 123.406 0.527 . . . . 0.0 112.105 -178.51 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -79.95 129.95 68.54 Favored Pre-proline 0 CA--C 1.535 0.372 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.398 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -64.16 -0.76 3.02 Favored 'Trans proline' 0 CA--C 1.541 0.86 0 C-N-CA 122.975 2.45 . . . . 0.0 114.528 178.663 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 28.9 pttt -81.08 -12.43 59.29 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 124.179 0.992 . . . . 0.0 111.545 172.341 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 19.4 m -110.35 102.02 10.69 Favored 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 125.998 1.719 . . . . 0.0 107.688 -173.393 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -85.94 145.82 26.97 Favored 'General case' 0 CA--C 1.53 0.197 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 175.571 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 39.2 t -138.77 105.98 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.208 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 176.614 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 1.7 mp -92.3 125.2 44.95 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.398 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 178.774 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -110.77 118.24 48.89 Favored Pre-proline 0 N--CA 1.451 -0.421 0 C-N-CA 126.132 1.773 . . . . 0.0 108.694 177.4 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -63.51 133.64 40.85 Favored 'Trans proline' 0 N--CA 1.451 -0.983 0 N-CA-C 108.725 -1.298 . . . . 0.0 108.725 168.364 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -87.33 -37.98 16.64 Favored 'General case' 0 N--CA 1.454 -0.252 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.1 t -88.41 137.63 30.6 Favored Pre-proline 0 CA--C 1.532 0.27 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 174.198 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -63.09 123.56 12.42 Favored 'Trans proline' 0 N--CA 1.451 -1.017 0 C-N-CA 121.733 1.622 . . . . 0.0 109.707 177.799 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 71.5 mt -73.83 117.4 15.56 Favored 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -179.467 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -82.65 179.09 7.89 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 124.58 1.152 . . . . 0.0 110.433 174.115 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -56.53 149.09 17.96 Favored 'General case' 0 N--CA 1.45 -0.453 0 CA-C-N 114.14 -1.391 . . . . 0.0 110.046 170.868 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 147.61 -147.15 17.63 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 29.5 m -143.23 144.25 32.07 Favored 'General case' 0 N--CA 1.452 -0.33 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 174.906 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' TYR . . . . . 0.412 ' HB3' HD11 ' A' ' 38' ' ' LEU . 93.7 m-85 -150.96 142.14 23.18 Favored 'General case' 0 N--CA 1.447 -0.625 0 N-CA-C 108.466 -0.938 . . . . 0.0 108.466 -159.428 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 19.6 tttt -124.51 124.74 42.94 Favored 'General case' 0 N--CA 1.453 -0.3 0 C-N-CA 123.883 0.873 . . . . 0.0 108.932 173.616 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.3 t -82.53 128.59 38.58 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 N-CA-C 105.453 -2.054 . . . . 0.0 105.453 165.079 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 50.3 m-20 -107.89 117.95 35.47 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 105.799 -1.926 . . . . 0.0 105.799 166.493 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.52 ' HZ3' ' O ' ' A' ' 93' ' ' ILE . 43.0 p-90 -112.27 149.38 32.43 Favored 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 123.654 0.781 . . . . 0.0 109.337 179.245 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 97.9 mtt180 -137.46 83.66 2.0 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 124.407 1.083 . . . . 0.0 108.68 -172.459 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.437 ' HB3' HG13 ' A' ' 93' ' ' ILE . . . -87.11 143.82 27.14 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 122.616 0.366 . . . . 0.0 111.086 178.594 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 54.8 t -149.43 152.78 11.6 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 C-N-CA 124.629 1.172 . . . . 0.0 108.517 -174.351 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 5.5 t -103.97 176.44 5.15 Favored 'General case' 0 CA--C 1.529 0.172 0 C-N-CA 123.865 0.866 . . . . 0.0 111.669 177.471 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -58.15 -57.77 11.39 Favored 'General case' 0 CA--C 1.53 0.174 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 166.42 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -62.69 -58.39 7.64 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 124.803 1.241 . . . . 0.0 110.314 -161.316 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.9 t 174.54 -160.11 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 128.092 2.557 . . . . 0.0 105.228 -176.411 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 3.6 t-80 67.82 84.79 0.15 Allowed Pre-proline 0 N--CA 1.455 -0.205 0 C-N-CA 126.074 1.75 . . . . 0.0 109.899 166.843 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -68.23 163.54 35.81 Favored 'Trans proline' 0 N--CA 1.441 -1.566 0 N-CA-C 108.899 -1.231 . . . . 0.0 108.899 171.754 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.52 ' O ' ' HZ3' ' A' ' 83' ' ' TRP . 0.8 OUTLIER -126.37 112.35 29.47 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.588 0 N-CA-C 103.251 -2.87 . . . . 0.0 103.251 150.368 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.25 148.97 29.22 Favored 'General case' 0 CA--C 1.509 -0.632 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 165.917 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -171.76 178.28 44.11 Favored Glycine 0 N--CA 1.446 -0.652 0 CA-C-N 114.098 -1.41 . . . . 0.0 111.185 -163.938 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -156.0 161.35 40.49 Favored 'General case' 0 N--CA 1.444 -0.756 0 C-N-CA 123.849 0.859 . . . . 0.0 111.48 -177.328 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 76.6 t -135.73 137.17 49.6 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.257 0 C-N-CA 125.999 1.72 . . . . 0.0 108.477 169.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 14.7 t -112.38 147.34 36.63 Favored 'General case' 0 N--CA 1.464 0.238 0 C-N-CA 125.17 1.388 . . . . 0.0 109.831 -179.254 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -158.34 161.03 37.58 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 123.576 0.75 . . . . 0.0 111.067 -178.128 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 27.3 mttp -123.29 141.13 52.31 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 125.263 1.425 . . . . 0.0 110.244 177.673 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.442 HG13 ' H ' ' A' ' 17' ' ' ALA . 42.5 t -117.14 118.44 58.7 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 106.652 -1.611 . . . . 0.0 106.652 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 31.7 mmtt . . . . . 0 C--O 1.249 1.069 0 CA-C-O 116.567 -1.682 . . . . 0.0 109.818 170.351 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.475 0.816 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -75.64 -179.73 5.41 Favored 'Trans proline' 0 N--CA 1.455 -0.791 0 C-N-CA 122.472 2.115 . . . . 0.0 110.279 176.239 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 18.9 mmtp 68.24 -148.06 0.13 Allowed 'General case' 0 CA--C 1.536 0.417 0 C-N-CA 124.881 1.272 . . . . 0.0 111.368 173.705 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -65.33 121.97 16.05 Favored 'General case' 0 CA--C 1.522 -0.117 0 CA-C-N 119.251 0.932 . . . . 0.0 110.843 -173.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 6.1 t -126.36 -47.65 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 C-N-CA 124.598 1.159 . . . . 0.0 110.088 -173.156 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 48.4 m -133.06 165.86 23.76 Favored 'General case' 0 N--CA 1.461 0.08 0 CA-C-O 121.216 0.531 . . . . 0.0 110.379 179.645 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 23.9 p -158.26 171.5 20.08 Favored 'General case' 0 N--CA 1.445 -0.709 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 69.2 m -145.72 79.37 11.24 Favored Pre-proline 0 C--N 1.328 -0.346 0 N-CA-C 104.962 -2.236 . . . . 0.0 104.962 153.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_endo -93.74 -83.07 0.0 OUTLIER 'Trans proline' 0 N--CA 1.44 -1.634 0 C-N-CA 123.755 2.97 . . . . 0.0 108.254 -176.211 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . 177.55 41.06 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 127.128 2.171 . . . . 0.0 111.141 177.273 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -51.28 94.72 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 124.47 1.108 . . . . 0.0 112.947 -174.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 57.41 33.07 65.17 Favored Glycine 0 CA--C 1.53 1.022 0 CA-C-N 115.848 -0.614 . . . . 0.0 112.319 -176.356 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 22.2 m -72.03 116.89 12.97 Favored 'General case' 0 N--CA 1.454 -0.23 0 CA-C-N 118.107 0.953 . . . . 0.0 108.45 173.598 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -116.73 111.8 20.29 Favored 'General case' 0 CA--C 1.514 -0.413 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 176.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 163.2 -55.34 0.29 Allowed Glycine 0 C--O 1.224 -0.516 0 C-N-CA 120.598 -0.81 . . . . 0.0 112.373 -175.37 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -157.17 146.75 20.43 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 117.728 0.764 . . . . 0.0 109.023 -167.05 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . 0.442 ' H ' HG13 ' A' ' 101' ' ' VAL . . . -47.25 133.26 9.55 Favored Pre-proline 0 CA--C 1.535 0.399 0 CA-C-O 119.083 -0.484 . . . . 0.0 111.404 168.789 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 83.7 Cg_endo -69.6 142.23 48.06 Favored 'Trans proline' 0 N--CA 1.45 -1.063 0 C-N-CA 121.789 1.659 . . . . 0.0 108.354 170.2 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -61.11 -42.57 98.76 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-O 121.263 0.554 . . . . 0.0 110.961 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.7 pttt -156.55 169.32 24.92 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 106.017 -1.845 . . . . 0.0 106.017 -179.388 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 1.8 mt -123.32 108.9 22.05 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.205 0 C-N-CA 124.339 1.056 . . . . 0.0 108.813 -179.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -97.75 136.83 37.54 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 124.684 1.194 . . . . 0.0 109.302 -177.089 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 53.4 mt -135.42 122.62 21.6 Favored 'General case' 0 N--CA 1.466 0.336 0 C-N-CA 124.812 1.245 . . . . 0.0 108.308 -178.639 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 29.3 m170 -123.91 112.65 17.49 Favored 'General case' 0 C--O 1.238 0.497 0 C-N-CA 123.716 0.806 . . . . 0.0 111.074 -165.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 8.3 m-85 -100.83 143.77 30.59 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 123.743 0.817 . . . . 0.0 110.688 -176.79 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 4.4 m -71.39 -43.44 66.83 Favored 'General case' 0 C--O 1.227 -0.099 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 170.55 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -78.09 134.16 37.76 Favored 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 179.248 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -78.19 70.94 4.63 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 107.055 -1.461 . . . . 0.0 107.055 162.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.738 HD12 HG23 ' A' ' 30' ' ' VAL . 3.5 pp -77.8 -170.54 1.91 Allowed 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 156.588 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.738 HG23 HD12 ' A' ' 29' ' ' LEU . 24.4 t 62.17 80.51 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.528 0.108 0 C-N-CA 125.327 1.451 . . . . 0.0 111.581 -168.491 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 62.8 m -75.41 -71.02 0.39 Allowed 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 160.01 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 16.7 tp60 -162.48 46.08 0.15 Allowed 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 123.133 0.573 . . . . 0.0 110.637 179.26 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 90.7 m-85 -142.6 21.72 2.0 Favored 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 123.146 0.578 . . . . 0.0 112.272 -171.31 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . 0.487 ' HB2' HG22 ' A' ' 30' ' ' VAL . 43.3 t -111.4 162.8 14.68 Favored 'General case' 0 CA--C 1.529 0.163 0 C-N-CA 124.146 0.978 . . . . 0.0 109.886 -174.757 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -166.22 174.14 41.75 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.623 -0.991 . . . . 0.0 110.623 173.28 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -156.62 157.9 36.09 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 173.161 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 85.5 mttt -146.58 170.35 17.09 Favored 'General case' 0 N--CA 1.454 -0.228 0 C-N-CA 123.962 0.905 . . . . 0.0 108.809 171.647 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.412 HD11 ' HB3' ' A' ' 79' ' ' TYR . 14.7 tp -131.47 127.23 36.92 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 -175.658 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 5.2 m -118.37 132.77 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.34 0 C-N-CA 123.576 0.751 . . . . 0.0 110.16 -179.349 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 27.3 ttt -81.53 82.79 7.19 Favored 'General case' 0 N--CA 1.446 -0.628 0 C-N-CA 124.836 1.254 . . . . 0.0 107.69 -178.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.413 HG22 ' O ' ' A' ' 41' ' ' THR . 11.4 m -81.06 58.26 3.41 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 125.054 1.341 . . . . 0.0 108.15 175.304 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -63.35 -59.63 4.45 Favored 'General case' 0 N--CA 1.456 -0.131 0 O-C-N 121.381 -0.824 . . . . 0.0 112.901 -173.558 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 3.6 ttt -157.09 123.34 2.52 Favored Pre-proline 0 N--CA 1.453 -0.308 0 N-CA-C 107.448 -1.316 . . . . 0.0 107.448 -172.35 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -79.05 44.19 1.64 Allowed 'Trans proline' 0 CA--C 1.537 0.656 0 C-N-CA 122.448 2.099 . . . . 0.0 111.086 -176.443 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -65.25 -53.33 33.59 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 109.931 -1.268 . . . . 0.0 109.931 -176.191 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 25.5 mmt -89.99 94.36 9.77 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 167.38 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 24.2 tt0 23.35 60.39 0.04 OUTLIER 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 129.248 3.019 . . . . 0.0 113.927 169.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 21.3 t-80 56.16 42.13 28.57 Favored 'General case' 0 CA--C 1.538 0.487 0 CA-C-N 115.516 -0.765 . . . . 0.0 112.755 169.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 67.8 m -93.04 90.33 0.43 Allowed Pre-proline 0 CA--C 1.541 0.612 0 C-N-CA 124.743 1.217 . . . . 0.0 111.965 175.275 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -74.79 170.37 20.52 Favored 'Trans proline' 0 N--CA 1.458 -0.585 0 C-N-CA 122.377 2.051 . . . . 0.0 110.343 172.31 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 25.3 mtt -123.68 120.66 33.38 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 123.149 0.58 . . . . 0.0 111.501 176.152 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.91 128.43 35.99 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 123.288 0.635 . . . . 0.0 110.686 177.291 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -106.22 162.27 5.23 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.452 0 C-N-CA 124.281 1.032 . . . . 0.0 110.669 -177.754 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 90.8 mttt -77.51 115.53 17.35 Favored 'General case' 0 C--O 1.234 0.287 0 C-N-CA 123.71 0.804 . . . . 0.0 110.726 177.362 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -137.2 152.93 50.44 Favored 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 125.138 1.375 . . . . 0.0 108.928 171.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -109.14 138.31 45.68 Favored 'General case' 0 N--CA 1.447 -0.6 0 C-N-CA 126.086 1.754 . . . . 0.0 108.366 174.42 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -101.41 119.66 49.91 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 106.642 -1.614 . . . . 0.0 106.642 173.166 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 50.1 m -119.41 178.17 4.64 Favored 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 106.652 -1.611 . . . . 0.0 106.652 174.383 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -128.46 159.92 22.05 Favored Glycine 0 N--CA 1.449 -0.489 0 N-CA-C 108.592 -1.803 . . . . 0.0 108.592 166.681 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -73.67 -173.41 27.19 Favored Glycine 0 CA--C 1.528 0.867 0 N-CA-C 108.956 -1.657 . . . . 0.0 108.956 165.524 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -45.89 -57.09 6.3 Favored Glycine 0 CA--C 1.53 0.98 0 C-N-CA 123.406 0.527 . . . . 0.0 112.105 -178.51 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -79.95 129.95 68.54 Favored Pre-proline 0 CA--C 1.535 0.372 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.398 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -64.16 -0.76 3.02 Favored 'Trans proline' 0 CA--C 1.541 0.86 0 C-N-CA 122.975 2.45 . . . . 0.0 114.528 178.663 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 28.9 pttt -81.08 -12.43 59.29 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 124.179 0.992 . . . . 0.0 111.545 172.341 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 19.4 m -110.35 102.02 10.69 Favored 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 125.998 1.719 . . . . 0.0 107.688 -173.393 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -85.94 145.82 26.97 Favored 'General case' 0 CA--C 1.53 0.197 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 175.571 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 39.2 t -138.77 105.98 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.208 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 176.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 1.7 mp -92.3 125.2 44.95 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.398 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 178.774 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -110.77 118.24 48.89 Favored Pre-proline 0 N--CA 1.451 -0.421 0 C-N-CA 126.132 1.773 . . . . 0.0 108.694 177.4 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -63.51 133.64 40.85 Favored 'Trans proline' 0 N--CA 1.451 -0.983 0 N-CA-C 108.725 -1.298 . . . . 0.0 108.725 168.364 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -87.33 -37.98 16.64 Favored 'General case' 0 N--CA 1.454 -0.252 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.1 t -88.41 137.63 30.6 Favored Pre-proline 0 CA--C 1.532 0.27 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 174.198 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -63.09 123.56 12.42 Favored 'Trans proline' 0 N--CA 1.451 -1.017 0 C-N-CA 121.733 1.622 . . . . 0.0 109.707 177.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 71.5 mt -73.83 117.4 15.56 Favored 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -179.467 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -82.65 179.09 7.89 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 124.58 1.152 . . . . 0.0 110.433 174.115 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -56.53 149.09 17.96 Favored 'General case' 0 N--CA 1.45 -0.453 0 CA-C-N 114.14 -1.391 . . . . 0.0 110.046 170.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 147.61 -147.15 17.63 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 29.5 m -143.23 144.25 32.07 Favored 'General case' 0 N--CA 1.452 -0.33 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 174.906 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . 0.412 ' HB3' HD11 ' A' ' 38' ' ' LEU . 93.7 m-85 -150.96 142.14 23.18 Favored 'General case' 0 N--CA 1.447 -0.625 0 N-CA-C 108.466 -0.938 . . . . 0.0 108.466 -159.428 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 19.6 tttt -124.51 124.74 42.94 Favored 'General case' 0 N--CA 1.453 -0.3 0 C-N-CA 123.883 0.873 . . . . 0.0 108.932 173.616 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.3 t -82.53 128.59 38.58 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 N-CA-C 105.453 -2.054 . . . . 0.0 105.453 165.079 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 50.3 m-20 -107.89 117.95 35.47 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 105.799 -1.926 . . . . 0.0 105.799 166.493 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.52 ' HZ3' ' O ' ' A' ' 93' ' ' ILE . 43.0 p-90 -112.27 149.38 32.43 Favored 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 123.654 0.781 . . . . 0.0 109.337 179.245 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 97.9 mtt180 -137.46 83.66 2.0 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 124.407 1.083 . . . . 0.0 108.68 -172.459 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.437 ' HB3' HG13 ' A' ' 93' ' ' ILE . . . -87.11 143.82 27.14 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 122.616 0.366 . . . . 0.0 111.086 178.594 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 54.8 t -149.43 152.78 11.6 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 C-N-CA 124.629 1.172 . . . . 0.0 108.517 -174.351 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 5.5 t -103.97 176.44 5.15 Favored 'General case' 0 CA--C 1.529 0.172 0 C-N-CA 123.865 0.866 . . . . 0.0 111.669 177.471 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -58.15 -57.77 11.39 Favored 'General case' 0 CA--C 1.53 0.174 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 166.42 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -62.69 -58.39 7.64 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 124.803 1.241 . . . . 0.0 110.314 -161.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.9 t 174.54 -160.11 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 128.092 2.557 . . . . 0.0 105.228 -176.411 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 3.6 t-80 67.82 84.79 0.15 Allowed Pre-proline 0 N--CA 1.455 -0.205 0 C-N-CA 126.074 1.75 . . . . 0.0 109.899 166.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -68.23 163.54 35.81 Favored 'Trans proline' 0 N--CA 1.441 -1.566 0 N-CA-C 108.899 -1.231 . . . . 0.0 108.899 171.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.52 ' O ' ' HZ3' ' A' ' 83' ' ' TRP . 0.8 OUTLIER -126.37 112.35 29.47 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.588 0 N-CA-C 103.251 -2.87 . . . . 0.0 103.251 150.368 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.25 148.97 29.22 Favored 'General case' 0 CA--C 1.509 -0.632 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 165.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -171.76 178.28 44.11 Favored Glycine 0 N--CA 1.446 -0.652 0 CA-C-N 114.098 -1.41 . . . . 0.0 111.185 -163.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -156.0 161.35 40.49 Favored 'General case' 0 N--CA 1.444 -0.756 0 C-N-CA 123.849 0.859 . . . . 0.0 111.48 -177.328 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 76.6 t -135.73 137.17 49.6 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.257 0 C-N-CA 125.999 1.72 . . . . 0.0 108.477 169.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 14.7 t -112.38 147.34 36.63 Favored 'General case' 0 N--CA 1.464 0.238 0 C-N-CA 125.17 1.388 . . . . 0.0 109.831 -179.254 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -158.34 161.03 37.58 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 123.576 0.75 . . . . 0.0 111.067 -178.128 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 27.3 mttp -123.29 141.13 52.31 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 125.263 1.425 . . . . 0.0 110.244 177.673 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.442 HG13 ' H ' ' A' ' 17' ' ' ALA . 42.5 t -117.14 118.44 58.7 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 106.652 -1.611 . . . . 0.0 106.652 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 31.7 mmtt . . . . . 0 C--O 1.249 1.069 0 CA-C-O 116.567 -1.682 . . . . 0.0 109.818 170.351 . . . . . . . . 0 0 . 1 stop_ save_